FDA Grants Orphan Drug Designation to CPI-613 for the Treatment of Peripheral T-Cell Lymphoma

August 21, 2018 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to CPI-613 for the treatment of peripheral T-cell lymphoma. CPI-613 is a novel lipoic acid analog with an anticancer activity that inhibits multiple enzyme targets within the tricarboxylic acid cycle. This drug is currently under investigation in combination with bendamustine in patients with relapsed or refractory T-cell lymphoma. T-cell lymphomas account for 10% to … (leggi tutto)